Insulet Corporation (PODD) has witnessed a notable increase of 3.5% today. Below is an in-depth analysis of the factors contributing to this price fluctuation.
Analysis: The ascent is seemingly correlated with rejuvenated vigor regarding Insulet’s Omnipods 5 product trajectory, following the announcement of a U.S. deployment of algorithm augmentations and expanded compatibility with continuous glucose monitors (CGMs).
With the American Diabetes Association (ADA) Scientific Sessions commencing on June 5, investors might be positioning themselves for supplementary clinical insights and product specifications that could both enhance adoption and fortify competitive standing.
Details: Insulet revealed a U.S. launch of improved Omnipods 5 algorithms, facilitated via an over-the-air software update through the controller or mobile application, with feature accessibility expanding as more compatible Pods are introduced.
This update cycle also expands compatibility to Abbott’s FreeStyle Libre 3 Plus sensor, potentially fostering user adoption by broadening CGM options.
Insulet plans to unveil further details during the ADA 86th Scientific Sessions running from June 5–8, 2026, which may serve as a significant catalyst for attention on diabetes technology entities.
The rally could reflect a “relief” response following heightened scrutiny concerning a voluntary medical device correction affecting specific lots of Omnipods, with today’s trading emphasizing progressive product advancements rather than manufacturing uncertainties.
$PODD Insider Trading Activity
In the past six months, insiders have engaged in $PODD stock transactions a total of seven times. Of these trades, five were purchases while two were sales.
Here is an outline of the recent insider transactions involving $PODD stock:
- ASHLEY MCEVOY (President and CEO) acquired 4,300 shares for an approximate value of $1,029,205.
- TIMOTHY C. STONESIFER executed two purchases, acquiring 3,752 shares for approximately $700,277 with no sales recorded.
- WAYNE A.I. FREDERICK sold 1,851 shares for an estimated $542,509.
- MICHAEL R MINOGUE acquired 2,030 shares for a value of $499,846.
- ELIZABETH H WEATHERMAN purchased 3,450 shares for approximately $497,489.
- LUCIANA BORIO sold 418 shares for an estimated $59,886.
To monitor insider activity, visit Quiver Quantitative’s insider trading dashboard. Further insider transaction data can be accessed through the Quiver Quantitative API insider transaction endpoint.
$PODD Hedge Fund Activity
Recently, 405 institutional investors have increased their holdings in $PODD, while 453 have reduced their positions during the last quarter.
Below are some of the most significant recent transactions:
- CAPITAL RESEARCH GLOBAL INVESTORS divested 2,739,416 shares (-62.1%) in Q1 2026, amounting to a value of approximately $574,839,053.
- FMR LLC reduced its holdings by 2,350,642 shares (-37.2%) in Q1 2026, equivalent to approximately $493,258,717.
- AQR CAPITAL MANAGEMENT LLC increased its stake by 1,139,609 shares (+248.2%) in Q1 2026, valued at an estimated $239,135,552.
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP raised its holdings by 1,011,369 shares (+462.7%) in Q1 2026, valued at approximately $212,225,670.
- JUPITER ASSET MANAGEMENT LTD added 475,438 shares (+202.8%) in Q1 2026, for an approximate value of $99,765,909.
- SOLEUS CAPITAL MANAGEMENT, L.P. increased its portfolio by 412,500 shares (+275.0%) in Q1 2026, approximating $86,559,000.
- TWO SIGMA INVESTMENTS, LP boosted its holdings by 395,627 shares (+107.9%) in Q1 2026, worth approximately $83,018,369.
To observe hedge fund activity, visit Quiver Quantitative’s institutional holdings dashboard. Data on hedge fund movements and 13F filings can be accessed through the Quiver Quantitative API 13F endpoint.
$PODD Congressional Stock Trading
In the past half-year, members of Congress have traded $PODD stock on two occasions. Notably, none were purchases, and two were sales.
Below is a summary of recent congressional trades involving $PODD stock:
SENATOR TINA SMITH recorded two transactions, comprising no purchases and two sales valued at up to $500,000 on 05/07 and 04/29.
To keep abreast of congressional trading, visit Quiver Quantitative’s congressional trading dashboard. Data on congressional stock trades can be accessed through the Quiver Quantitative API Congress trades endpoint.
$PODD Analyst Ratings
Wall Street analysts have recently commented on $PODD, with three firms designating buy ratings and one issuing a sell rating.
Here are some of the latest analyst evaluations:
- William Blair assigned an “Outperform” rating on 05/20/2026
- JP Morgan issued an “Overweight” rating on 05/07/2026
- Barclays rendered an “Underweight” rating on 01/12/2026
- Truist Securities declared a “Buy” rating on 12/18/2025
For ongoing insights on analyst ratings and price projections for $PODD, visit Quiver Quantitative’s $PODD forecast page.
$PODD Price Targets
Numerous analysts have recently articulated price targets for $PODD. A total of 17 analysts have issued price estimates, with a median target set at $249.0.
Here are some of the notable recent targets:
- Joanne Wuensch from Citigroup established a target price of $165.0 on 05/28/2026
- Shagun Singh from RBC Capital set a target price of $280.0 on 05/27/2026
- Marie Thibault from BTIG articulated a target price of $235.0 on 05/27/2026
- Travis Steed from B of A Securities established a target price of $208.0 on 05/18/2026
- Matt Miksic from Barclays proposed a target price of $198.0 on 05/08/2026
- Lawrence Biegelsen from Wells Fargo designated a target price of $255.0 on 05/07/2026
- William Plovanic from Canaccord Genuity set a target price of $249.0 on 05/07/2026
Source link: Quiverquant.com.
